Baird Capital has announced the final close of its fourth venture capital fund with a total of $185 million in committed capital.
This figure exceeds Baird's original goal of $150 million and the size of its previous fund ($171 million, according to a Crain's report).
Fund IV will focus on technology and services companies, healthcare, diagnostics and medical devices. Baird Capital has invested prior funds in healthcare.
Baird indicated Fund IV has already invested in five companies: Catalyze, emids, Integrated Diagnostics, NeuMoDx Molecular and WordStream.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.